Can pressurised intraperitoneal aerosol chemotherapy with oxaliplatin (PIPAC-O+) be added to standard treatment for resectable high-risk gastric cancer patients? A study protocol.
Jessica L ReidHarsh A KanherePeter J HewettTimothy J PriceGuy J MaddernMarkus I TrochslerPublished in: Pleura and peritoneum (2021)
This is a prospective, single centre, non-randomised, open-label pilot trial evaluating the addition of PIPAC to the standard multimodal treatment pathway. Patients will undergo standard neoadjuvant chemotherapy with four cycles of fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT), then PIPAC, followed by gastrectomy. Four cycles of FLOT will be administered post-surgery. Primary outcome is safety and feasibility, assessed by perioperative morbidity and possible interruptions of the standard multimodal treatment pathway.
Keyphrases
- open label
- neoadjuvant chemotherapy
- locally advanced
- study protocol
- clinical trial
- minimally invasive
- end stage renal disease
- squamous cell carcinoma
- pain management
- ejection fraction
- radiation therapy
- cardiac surgery
- coronary artery disease
- acute kidney injury
- replacement therapy
- combination therapy
- coronary artery bypass
- peritoneal dialysis
- percutaneous coronary intervention